NCT07141368View on ClinicalTrials.gov

Single Oral Dose Comparative Bioavailability Study of Investigational Product in Healthy Human Subjects Under Fasting Conditions.

NANot yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

November 1, 2025

Study Completion Date

November 1, 2025

Conditions

Healthy Volunteer

Interventions

OTHER

Curcumin Dispersome formulation

75% BLG (600 mg (2 capsules of 300 mg each, containing 90 mg curcumin per capsule

OTHER

Non-formulated Curcumin

dose: 90 mg, 1 capsule

OTHER

Benchmark Formulation 1 - Turmipure Gold™

recommended daily dose: 300 mg, 1 capsule

OTHER

Benchmark Formulation 2 - Qunol, Turmeric, Curcumin Complex, Extra Strength

recommended daily dose: 1000 mg, 2 capsules of 500 mg each

Trial Locations (1)

500051

IndiGlobal Labs Pvt. Ltd, Hyderabad

All Listed Sponsors

lead

Vedic Lifesciences Pvt. Ltd.

INDUSTRY

NCT07141368 - Single Oral Dose Comparative Bioavailability Study of Investigational Product in Healthy Human Subjects Under Fasting Conditions. | Biotech Hunter | Biotech Hunter